Please enable JavaScript to continue using this application.

Compare $ENTA vs $XFOR | Chartloom

Compare

$ENTA vs $XFOR

Enanta Pharmaceuticals Inc · X4 Pharmaceuticals Inc

ENTA

Enanta Pharmaceuticals Inc

XFOR

X4 Pharmaceuticals Inc

Compare $ENTA vs $XFOR

Comparing Enanta Pharmaceuticals Inc and X4 Pharmaceuticals Inc

ENTAEnanta Pharmaceuticals Inc

XFORX4 Pharmaceuticals Inc

ENTAEnanta Pharmaceuticals Inc

Market cap

$364M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

6.51x

Rev growth (TTM)

0.7%

YTD performance

-13.3%

52W performance

10.6%

FCF yield

-10.2%

XFORX4 Pharmaceuticals Inc

Market cap

$274M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

28.09x

Rev growth (TTM)

-51.6%

YTD performance

-25.2%

52W performance

-12.3%

FCF yield

-32.3%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ENTA

XFOR

Detailed metrics comparison

ENTA

Enanta Pharmaceuticals Inc

XFOR

X4 Pharmaceuticals Inc

Market Cap

ENTA$364M

XFOR$274M

Enterprise Value

ENTA$456M

XFOR$156M

Price

ENTA$12.50

XFOR$2.91

P/E Ratio

ENTAN/A

XFORN/A

P/S Ratio

ENTA5.57x

XFOR17.32x

EV/Sales

ENTA6.99x

XFOR9.85x

EV/EBITDA

ENTA31.83x

XFOR0.00x

P/B Ratio

ENTA3.73x

XFOR1.81x

P/FCF Ratio

ENTAN/A

XFORN/A

EV/FCF

ENTA-12.36x

XFOR-1.76x

PEG Ratio

ENTAN/A

XFORN/A

Forward P/E (NTM)

ENTAN/A

XFORN/A

Forward P/S (NTM)

ENTA6.51x

XFOR28.09x

Revenue (TTM)

ENTA$65M

XFOR$16M

Revenue Growth (YoY)

ENTA0.7%

XFOR-51.6%

Forward Rev Growth

ENTA-7.3%

XFOR-27.7%

Gross Margin (TTM)

ENTA0.0%

XFOR81.5%

Operating Margin (TTM)

ENTA0.0%

XFOR0.0%

EBITDA Margin (TTM)

ENTA-82.5%

XFOR-544.2%

Net Margin (TTM)

ENTA-96.9%

XFOR-568.8%

FCF Margin (TTM)

ENTA-56.6%

XFOR-560.0%

Net Income (TTM)

ENTA$-63M

XFOR$-90M

FCF (TTM)

ENTA$-37M

XFOR$-89M

EPS (TTM)

ENTA-$2.17

XFOR-$0.71

ROE (TTM)

ENTA-6184.0%

XFOR-6305.0%

ROA (TTM)

ENTA-2070.0%

XFOR-3689.0%

ROIC (TTM)

ENTA-2677.0%

XFOR-4109.0%

Cash

ENTA$33M

XFOR$195M

Debt

ENTA$126M

XFOR$77M

Net Cash/Debt

ENTA$-93M

XFOR$118M

Current Ratio (TTM)

ENTA3.76x

XFOR11.30x

Quick Ratio (TTM)

ENTA3.62x

XFOR10.87x

Debt/Equity (TTM)

ENTA1.25x

XFOR0.49x

Debt/Assets (TTM)

ENTA0.0%

XFOR0.0%

Interest Coverage (TTM)

ENTAN/A

XFORN/A

Net Debt/EBITDA (TTM)

ENTA0.00x

XFOR0.00x

Beta

ENTA0.72

XFOR0.50

52W Performance

ENTA10.6%

XFOR-12.3%

YTD Performance

ENTA-13.3%

XFOR-25.2%

% from 52W High

ENTA-27.1%

XFOR-39.8%

% from 52W Low

ENTA22.5%

XFOR7.8%

Asset Turnover (TTM)

ENTA0.21x

XFOR0.06x

FCF Yield (TTM)

ENTA-10.2%

XFOR-32.3%

Earnings Yield (TTM)

ENTA-17.4%

XFOR-32.8%

Dividend Yield (TTM)

ENTAN/A

XFORN/A

Rule of 40

ENTA-55.9

XFOR-611.6

EV/GP/RG

ENTAN/A

XFORN/A

Ticker research

View ENTA research View XFOR research

Metric	ENTA Enanta Pharmaceuticals Inc	XFOR X4 Pharmaceuticals Inc
Market & Valuation
Market Cap	$364M	$274M
Enterprise Value	$456M	$156M
Price	$12.50	$2.91
P/E Ratio	N/A	N/A
P/S Ratio	5.57x	17.32x
EV/Sales	6.99x	9.85x
EV/EBITDA	31.83x	0.00x
P/B Ratio	3.73x	1.81x
P/FCF Ratio	N/A	N/A
EV/FCF	-12.36x	-1.76x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	6.51x	28.09x
Revenue & Growth
Revenue (TTM)	$65M	$16M
Revenue Growth (YoY)	0.7%	-51.6%
Forward Rev Growth	-7.3%	-27.7%
Profitability
Gross Margin (TTM)	0.0%	81.5%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-82.5%	-544.2%
Net Margin (TTM)	-96.9%	-568.8%
FCF Margin (TTM)	-56.6%	-560.0%
Net Income (TTM)	$-63M	$-90M
FCF (TTM)	$-37M	$-89M
EPS (TTM)	-$2.17	-$0.71
ROE (TTM)	-6184.0%	-6305.0%
ROA (TTM)	-2070.0%	-3689.0%
ROIC (TTM)	-2677.0%	-4109.0%
Financial Health
Cash	$33M	$195M
Debt	$126M	$77M
Net Cash/Debt	$-93M	$118M
Current Ratio (TTM)	3.76x	11.30x
Quick Ratio (TTM)	3.62x	10.87x
Debt/Equity (TTM)	1.25x	0.49x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.72	0.50
52W Performance	10.6%	-12.3%
YTD Performance	-13.3%	-25.2%
% from 52W High	-27.1%	-39.8%
% from 52W Low	22.5%	7.8%
Efficiency & Yields
Asset Turnover (TTM)	0.21x	0.06x
FCF Yield (TTM)	-10.2%	-32.3%
Earnings Yield (TTM)	-17.4%	-32.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-55.9	-611.6
EV/GP/RG	N/A	N/A
Ticker research	View ENTA research	View XFOR research

Valuation

P/S Ratio

ENTA

5.57x

XFOR

17.32x

EV/FCF

ENTA

-12.36x

XFOR

-1.76x

Growth & revenue

Revenue Growth TTM

ENTA

0.7%

XFOR

-51.6%

Forward Revenue Growth

ENTA

-7.3%

XFOR

-27.7%

Profitability & performance

Gross Margin

XFOR

81.5%

ENTA

0.0%

ROE

ENTA

-6184.0%

XFOR

-6305.0%

FCF Yield %

ENTA

-10.2%

XFOR

-32.3%

52-Week Performance

ENTA

10.6%

XFOR

-12.3%

Detailed metrics comparison

ENTA

Enanta Pharmaceuticals Inc

XFOR

X4 Pharmaceuticals Inc

Market Cap

ENTA$364M

XFOR$274M

Enterprise Value

ENTA$456M

XFOR$156M

Price

ENTA$12.50

XFOR$2.91

P/E Ratio

ENTAN/A

XFORN/A

P/S Ratio

ENTA5.57x

XFOR17.32x

EV/Sales

ENTA6.99x

XFOR9.85x

EV/EBITDA

ENTA31.83x

XFOR0.00x

P/B Ratio

ENTA3.73x

XFOR1.81x

P/FCF Ratio

ENTAN/A

XFORN/A

EV/FCF

ENTA-12.36x

XFOR-1.76x

PEG Ratio

ENTAN/A

XFORN/A

Forward P/E (NTM)

ENTAN/A

XFORN/A

Forward P/S (NTM)

ENTA6.51x

XFOR28.09x

Revenue (TTM)

ENTA$65M

XFOR$16M

Revenue Growth (YoY)

ENTA0.7%

XFOR-51.6%

Forward Rev Growth

ENTA-7.3%

XFOR-27.7%

Gross Margin (TTM)

ENTA0.0%

XFOR81.5%

Operating Margin (TTM)

ENTA0.0%

XFOR0.0%

EBITDA Margin (TTM)

ENTA-82.5%

XFOR-544.2%

Net Margin (TTM)

ENTA-96.9%

XFOR-568.8%

FCF Margin (TTM)

ENTA-56.6%

XFOR-560.0%

Net Income (TTM)

ENTA$-63M

XFOR$-90M

FCF (TTM)

ENTA$-37M

XFOR$-89M

EPS (TTM)

ENTA-$2.17

XFOR-$0.71

ROE (TTM)

ENTA-6184.0%

XFOR-6305.0%

ROA (TTM)

ENTA-2070.0%

XFOR-3689.0%

ROIC (TTM)

ENTA-2677.0%

XFOR-4109.0%

Cash

ENTA$33M

XFOR$195M

Debt

ENTA$126M

XFOR$77M

Net Cash/Debt

ENTA$-93M

XFOR$118M

Current Ratio (TTM)

ENTA3.76x

XFOR11.30x

Quick Ratio (TTM)

ENTA3.62x

XFOR10.87x

Debt/Equity (TTM)

ENTA1.25x

XFOR0.49x

Debt/Assets (TTM)

ENTA0.0%

XFOR0.0%

Interest Coverage (TTM)

ENTAN/A

XFORN/A

Net Debt/EBITDA (TTM)

ENTA0.00x

XFOR0.00x

Beta

ENTA0.72

XFOR0.50

52W Performance

ENTA10.6%

XFOR-12.3%

YTD Performance

ENTA-13.3%

XFOR-25.2%

% from 52W High

ENTA-27.1%

XFOR-39.8%

% from 52W Low

ENTA22.5%

XFOR7.8%

Asset Turnover (TTM)

ENTA0.21x

XFOR0.06x

FCF Yield (TTM)

ENTA-10.2%

XFOR-32.3%

Earnings Yield (TTM)

ENTA-17.4%

XFOR-32.8%

Dividend Yield (TTM)

ENTAN/A

XFORN/A

Rule of 40

ENTA-55.9

XFOR-611.6

EV/GP/RG

ENTAN/A

XFORN/A

Ticker research

View ENTA research View XFOR research

Metric	ENTA Enanta Pharmaceuticals Inc	XFOR X4 Pharmaceuticals Inc
Market & Valuation
Market Cap	$364M	$274M
Enterprise Value	$456M	$156M
Price	$12.50	$2.91
P/E Ratio	N/A	N/A
P/S Ratio	5.57x	17.32x
EV/Sales	6.99x	9.85x
EV/EBITDA	31.83x	0.00x
P/B Ratio	3.73x	1.81x
P/FCF Ratio	N/A	N/A
EV/FCF	-12.36x	-1.76x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	6.51x	28.09x
Revenue & Growth
Revenue (TTM)	$65M	$16M
Revenue Growth (YoY)	0.7%	-51.6%
Forward Rev Growth	-7.3%	-27.7%
Profitability
Gross Margin (TTM)	0.0%	81.5%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-82.5%	-544.2%
Net Margin (TTM)	-96.9%	-568.8%
FCF Margin (TTM)	-56.6%	-560.0%
Net Income (TTM)	$-63M	$-90M
FCF (TTM)	$-37M	$-89M
EPS (TTM)	-$2.17	-$0.71
ROE (TTM)	-6184.0%	-6305.0%
ROA (TTM)	-2070.0%	-3689.0%
ROIC (TTM)	-2677.0%	-4109.0%
Financial Health
Cash	$33M	$195M
Debt	$126M	$77M
Net Cash/Debt	$-93M	$118M
Current Ratio (TTM)	3.76x	11.30x
Quick Ratio (TTM)	3.62x	10.87x
Debt/Equity (TTM)	1.25x	0.49x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.72	0.50
52W Performance	10.6%	-12.3%
YTD Performance	-13.3%	-25.2%
% from 52W High	-27.1%	-39.8%
% from 52W Low	22.5%	7.8%
Efficiency & Yields
Asset Turnover (TTM)	0.21x	0.06x
FCF Yield (TTM)	-10.2%	-32.3%
Earnings Yield (TTM)	-17.4%	-32.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-55.9	-611.6
EV/GP/RG	N/A	N/A
Ticker research	View ENTA research	View XFOR research